Instead, allogeneic hematopoietic stem cell transplant (HSCT) and adoptive cell therapy with donor-derived, allogeneic NK cells (Figure 2) are attractive alternatives to augment the graft-versus-tumor effect of NK cells generated by KIR mismatch [27,28]. Here, KIR3DL1 is linked to neoplasm.